GLP-1 Drugs and Sleep Apnea — A Breakthrough?

Join host Julia Cartwright as she explores the surprising connection between GLP-1 medications and sleep apnea treatment. Discover how this emerging drug class is challenging traditional approaches to one of America's most common sleep disorders, offering new hope beyond weight loss.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

Julia Cartwright examines who gets left behind as tirzepatide becomes the first FDA-approved drug for sleep apnea with obesity. We discuss cost barriers, insurance gaps, and equity concerns surrounding this breakthrough treatment, covering real-world access challenges that prevent many patients from benefiting despite promising trial results.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

Host Julia Cartwright explores how tirzepatide, the first FDA-approved medication for obstructive sleep apnea, works beyond simple weight loss. Drawing on SURMOUNT-OSA trial data, the episode examines emerging evidence that these GLP-1 drugs may combat sleep apnea through multiple pathways: reducing airway inflammation, improving insulin sensitivity, and potentially influencing brain receptors that regulate breathing and sleep patterns during rest.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

Julia Cartwright explores how tirzepatide (Zepbound) became the first FDA-approved medication for obstructive sleep apnea in adults with obesity. She examines the groundbreaking SURMOUNT-OSA trials, which showed dramatic reductions in breathing disruptions and achieved disease remission in up to 50% of participants, offering new hope beyond CPAP machines.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.